MX349996B - Metodos y composiciones para diagnostico y tratamiento del cancer. - Google Patents

Metodos y composiciones para diagnostico y tratamiento del cancer.

Info

Publication number
MX349996B
MX349996B MX2015016088A MX2015016088A MX349996B MX 349996 B MX349996 B MX 349996B MX 2015016088 A MX2015016088 A MX 2015016088A MX 2015016088 A MX2015016088 A MX 2015016088A MX 349996 B MX349996 B MX 349996B
Authority
MX
Mexico
Prior art keywords
diagnosis
cancer
compositions
treatment
methods
Prior art date
Application number
MX2015016088A
Other languages
English (en)
Inventor
Sahin Ugur
Tuereci Oezlem
Koslowski Michael
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of MX349996B publication Critical patent/MX349996B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método para detectar un péptido antigénico tumoral que comprende la secuencia de aminoácidos de un antígeno tumoral codificado por una secuencia de ácidos nucleicos de SEQ ID NO: 1 en un paciente, el método caracterizado porque comprende poner en contacto una muestra biológica aislada de dicho paciente con un anticuerpo que enlaza a los aminoácidos 120-132 de SEQ ID NO: 2 para formar un complejo detectable, y detectar si dicho péptido antigénico tumoral está presente en dicha muestra al detectar la formación de dicho complejo.
MX2015016088A 2009-02-20 2010-02-18 Metodos y composiciones para diagnostico y tratamiento del cancer. MX349996B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15415909P 2009-02-20 2009-02-20
EP09002458A EP2221063A1 (en) 2009-02-20 2009-02-20 Methods and compositions for diagnosis and treatment of cancer
PCT/EP2010/001035 WO2010094490A1 (en) 2009-02-20 2010-02-18 Methods and compositions for diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
MX349996B true MX349996B (es) 2017-08-23

Family

ID=40594202

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015016088A MX349996B (es) 2009-02-20 2010-02-18 Metodos y composiciones para diagnostico y tratamiento del cancer.
MX2011008429A MX2011008429A (es) 2009-02-20 2010-02-18 Metodos y composiciones para diagnostico y tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011008429A MX2011008429A (es) 2009-02-20 2010-02-18 Metodos y composiciones para diagnostico y tratamiento del cancer.

Country Status (14)

Country Link
US (1) US9637548B2 (es)
EP (3) EP2221063A1 (es)
JP (2) JP5809067B2 (es)
KR (1) KR20110128315A (es)
CN (1) CN102325548A (es)
AU (1) AU2010215691B2 (es)
BR (1) BRPI1008566A8 (es)
CA (1) CA2750980A1 (es)
IL (1) IL214255B (es)
MX (2) MX349996B (es)
NZ (2) NZ601793A (es)
SG (2) SG173033A1 (es)
WO (1) WO2010094490A1 (es)
ZA (1) ZA201105472B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
FI2398902T3 (fi) 2009-02-20 2023-11-28 Astellas Pharma Inc Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten
AU2015255252B2 (en) * 2009-02-20 2017-11-23 BioNTech SE Methods and compositions for diagnosis and treatment of cancer
KR102126964B1 (ko) 2009-11-11 2020-06-25 가니메드 파마슈티칼스 게엠베하 클라우딘 6 특이적 항체
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
DK3026064T3 (en) 2011-05-13 2019-01-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6
EP2750694B8 (en) 2011-08-08 2018-11-14 Curelab Oncology, Inc. Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
RU2639540C2 (ru) * 2011-08-10 2017-12-21 Ланкенау Инститьют Фо Медикал Ресёрч Способы и композиции для лечения аутоиммунных и воспалительных заболеваний
EP2875046B1 (en) 2012-07-19 2020-02-26 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
KR101329655B1 (ko) * 2012-12-13 2013-11-14 강원대학교산학협력단 수압식 안마장치 및 그의 제어방법
US10329353B2 (en) * 2013-03-05 2019-06-25 Board Of Regents, The University Of Texas System Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
TWI819228B (zh) * 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
CN104634907B (zh) * 2013-11-11 2018-04-20 上海交通大学医学院附属瑞金医院 一类氨基酸分子组合作为胃癌标志物的用途
CN110123837A (zh) * 2018-02-02 2019-08-16 科济生物医药（上海）有限公司 细胞免疫治疗的组合
US20230310500A1 (en) * 2020-09-03 2023-10-05 Techno Craft Corporation Ltd. Use of Immune Killer Cell Against Circulating Tumor Cells in Solid Tumor Treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) * 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
JP2002536995A (ja) * 1999-02-22 2002-11-05 インサイト・ファーマスーティカルズ・インコーポレイテッド 結腸の疾患に関連する遺伝子
DK1309726T4 (en) 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
EP2000482A1 (en) * 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2006033664A1 (en) 2004-03-08 2006-03-30 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2009126926A2 (en) * 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
FI2398902T3 (fi) * 2009-02-20 2023-11-28 Astellas Pharma Inc Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten
EP2875046B1 (en) * 2012-07-19 2020-02-26 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof

Also Published As

Publication number Publication date
EP2398497A1 (en) 2011-12-28
EP3170511A1 (en) 2017-05-24
US20110318264A1 (en) 2011-12-29
AU2010215691B2 (en) 2015-09-03
JP5809067B2 (ja) 2015-11-10
BRPI1008566A8 (pt) 2018-01-02
JP2016040253A (ja) 2016-03-24
NZ594479A (en) 2013-06-28
BRPI1008566A2 (pt) 2017-06-06
WO2010094490A1 (en) 2010-08-26
US9637548B2 (en) 2017-05-02
SG10201402491YA (en) 2014-07-30
CA2750980A1 (en) 2010-08-26
JP2012518608A (ja) 2012-08-16
IL214255A0 (en) 2011-09-27
EP2221063A1 (en) 2010-08-25
CN102325548A (zh) 2012-01-18
IL214255B (en) 2018-05-31
ZA201105472B (en) 2012-10-31
NZ601793A (en) 2013-11-29
KR20110128315A (ko) 2011-11-29
MX2011008429A (es) 2011-09-29
SG173033A1 (en) 2011-08-29
AU2010215691A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
MX2011008429A (es) Metodos y composiciones para diagnostico y tratamiento del cancer.
MX345316B (es) Métodos y composiciones para diagnóstico y tratamiento del cáncer.
EA201590986A1 (ru) Антитела к ceacam5 и их применения
WO2016161410A3 (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
WO2009053041A3 (en) Identification of tumor-associated markers for diagnosis and therapy
MY162741A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin D1
WO2011073629A3 (en) Cancer diagnosis and treatment
BR112012020373A2 (pt) anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tata419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
EP2285989A4 (en) NEW TARGETS TO REGULATE ANGIOGENESIS
EP2373794A4 (en) NECTINE-4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS OF CANCER
MX2009012271A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de her3.
WO2010048144A3 (en) Imaging and radiotherapy methods
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
MX2011004979A (es) N-cadherina:blanco para diagnosis y terapia de cancer.
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
UA113413C2 (uk) Пептид mphosph1 та вакцина, що його містить
WO2009008990A3 (en) Methods and compositions for treatment of cancer and other angiogenesis - related diseases
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer